130.12
5.23 (4.19%)
| Previous Close | 124.89 |
| Open | 125.27 |
| Volume | 2,197,118 |
| Avg. Volume (3M) | 2,197,961 |
| Market Cap | 17,253,902,336 |
| Price / Sales | 14.79 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2026 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Guardant Health, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -3.5 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.20 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HIDALGO MEDINA MANUEL | - | 133.22 | -1,000 | -133,220 |
| JOYCE MEGHAN V. | - | 127.03 | -10,000 | -1,270,300 |
| KROGNES STEVE E. | - | 133.06 | -9,294 | -1,236,660 |
| SAIA JOHN G. | - | 127.51 | -10,000 | -1,275,100 |
| Aggregate Net Quantity | -30,294 | |||
| Aggregate Net Value ($) | -3,915,280 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 130.21 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KROGNES STEVE E. | Director | 04 Jun 2026 | Sell (-) | 9,294 | 133.06 | 1,236,660 |
| JOYCE MEGHAN V. | Director | 03 Jun 2026 | Sell (-) | 10,000 | 127.03 | 1,270,300 |
| JOYCE MEGHAN V. | Director | 03 Jun 2026 | Option execute | 10,000 | - | - |
| KROGNES STEVE E. | Director | 31 May 2026 | Option execute | 154 | - | - |
| HIDALGO MEDINA MANUEL | Director | 28 May 2026 | Sell (-) | 1,000 | 133.22 | 133,220 |
| SAIA JOHN G. | Officer | 27 May 2026 | Sell (-) | 10,000 | 127.51 | 1,275,100 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |